Following positive Phase IIb TACTI-003 data, the FDA has endorsed further evaluation of Immutep’s efti-Keytruda combination in first-line recurrent/metastatic HNSCC patients with PD-L1 CPS <1, a ...

During the NFL Networks' Tuesday training camp coverage, a former Iowa football legend interrupted to share his view on the ...

Discover Novavax's Q2 2025 earnings insights: raised revenue targets, cost reductions, key partnerships with Sanofi & Takeda, and progress in ...

The US Department of Health and Human Services has terminated 22 mRNA vaccine research contracts under BARDA, signaling a ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

The Trump administration’s decision to terminate hundreds of millions of dollars to develop mRNA vaccines and treatments imperils the country’s ability to fight future pandemics and is built on false ...

While anti-vaxxers are thrilled, experts warn that defunding mRNA development takes away our already-proven best weapon ...

Has this ever happened to you? Misplacing your reading glasses, almost daily? Forgetting names, even of good friends ...

Overall, the initial steps of the wind-down will result the in the cancellation of nearly $500 million. Not all mRNA related ...

Keyron announced today that it made significant personnel appointments as it prepares for clinical trials for its ForePass ...

Eftilagimod alfa shows promise as a novel immunotherapy for head and neck cancer patients with low PD-L1 expression, offering ...

Q2 2025 Earnings Call Transcript August 4, 2025 Syndax Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0 ...